Introduction
Switzerland’s Patent Act revision takes effect on January 1, 2027. It is the most significant update to Swiss domestic patent law in decades, and it changes two things that directly affect FTO strategy for pharma and medtech companies planning Swiss market entry.
First, the IPI administrative opposition procedure is abolished. The 9-month window after patent grant during which any party could challenge a Swiss domestic patent at relatively low cost and without full court proceedings closes permanently on that date. After January 2027, validity challenges go directly to the Swiss Federal Patent Court. Second, the protection scope of Swiss domestic patents is aligned with EPO standards. Patents that would previously have been assessed under a narrower Swiss-specific scope standard now carry EPO-comparable protection breadth.
Neither of these changes is cosmetic. Together they mean that the Swiss patent landscape a pharma or medtech product will face after January 2027 is materially different from the one it would have faced in 2025 or 2026. And there is a defined pre-reform window — between now and January 1, 2027 — in which specific actions are available that will not be available after the reform takes effect. This article covers both changes, what the pre-reform window offers, and what a complete post-reform Swiss FTO needs to address.
The Swiss Patent Landscape: Two Layers That Both Matter for FTO
Switzerland’s patent landscape for any pharma or medtech product has two distinct layers, and an accurate FTO needs to cover both.
EPO-granted European patents validated in Switzerland: European patents granted by the EPO can be validated in Switzerland through the standard EPO national phase process. These patents are governed by Swiss law for infringement and validity purposes, litigated before the Swiss Federal Patent Court, and not subject to UPC jurisdiction — Switzerland is not a UPC participating state. This is the layer that most international FTO analyses already cover. It is important but not complete.
Domestic IPI-granted Swiss patents: Switzerland has its own domestic patent system, administered by the Swiss Federal Institute of Intellectual Property (IPI). Swiss domestic patents are separate rights from EPO-validated European patents — not equivalent, not interchangeable. Major Swiss companies in pharma (Novartis, Roche) and medtech (Straumann, Sonova, Ypsomed) hold significant domestic Swiss patent portfolios covering device designs, formulation methods, manufacturing processes, and software-integrated systems. Most international FTO analyses underweight this domestic layer — a systematic gap that the reform’s scope alignment change makes more consequential.
Why the asymmetry between them is closing: Under current law, Swiss domestic patents operate under a slightly different protection scope standard than EPO-validated European patents. The difference is subtle but commercially material in technology sectors where the boundary between infringing and non-infringing products is narrow — precisely the kind of technology boundary that defines pharma compound claims and medtech device claims. The reform’s scope alignment closes this asymmetry. Post-reform, both layers carry EPO-comparable protection scope. The domestic Swiss patent layer is becoming more significant, not less.
SWISS FTO CONTEXT: Switzerland is not a UPC participating state. Swiss patents are governed entirely by Swiss law and litigated before the Swiss Federal Patent Court — not the UPC, not the EPO opposition division, not any German court. UPC long-arm jurisdiction can reach Swiss products under certain conditions (as confirmed in HL Display v Black Sheep, 2025) but the Swiss patent register itself sits entirely outside the UPC system. A complete Swiss FTO covers both the domestic IPI register and EPO-validated patents under Swiss law.
Change One: IPI Opposition Abolished — What It Means for FTO
What the IPI opposition procedure was: Under current Swiss patent law, any party can file an administrative opposition against a granted Swiss domestic patent within 9 months of grant. The opposition is handled by the IPI — not the Swiss Federal Patent Court — and is a significantly lower-cost and faster validity challenge mechanism than full FPC nullity proceedings. The opposition procedure has served as a filter on weak Swiss domestic patents: a granted patent that is not opposed within 9 months may carry an inference of validity, while a patent that survives opposition has been tested. Under the revised Act, this procedure is abolished entirely.
Why abolition changes FTO risk assessment: The IPI opposition procedure affected FTO risk assessment in two ways. First, an unopposed Swiss domestic patent — one that passed through the 9-month window without challenge — carried a modest inference of validity: someone assessed it and decided it wasn’t worth opposing. Post-reform, this inference disappears because the procedure no longer exists. An unopposed post-reform Swiss patent carries no such inference — it simply means no one was required to pay the relatively low cost of an IPI challenge. Second, the opposition procedure gave market entrants a low-cost path to challenge genuinely weak blocking patents before incurring Swiss FPC litigation costs. Post-reform, the same challenge requires full FPC nullity proceedings — more resource-intensive and more time-consuming.
The interaction between IPI opposition abolition and the Swiss FPC’s new expedited nullity proceedings — which now complete validity challenges within 12 months where a challenged patent is the basis of an active infringement action — is analysed in depth in our piece on the Swiss Federal Patent Court’s expedited nullity proceedings and their implications for pharma and medtech portfolios. The FPC expedited procedure is the post-reform replacement for IPI opposition as the primary validity challenge route — but it operates at a materially higher resource level and within the context of active infringement proceedings rather than as a standalone administrative challenge.
The pre-reform window — now or never: Any Swiss domestic patent currently within its 9-month IPI opposition window that carries genuine validity vulnerabilities represents a time-limited opportunity. Once January 1, 2027 passes, the IPI opposition mechanism closes permanently. The same challenge that would cost a fraction of FPC nullity proceedings today will require full court proceedings tomorrow. For pharma and medtech companies with Swiss launches planned and blocking domestic Swiss patents identified in their FTO, the pre-reform opposition window is a strategic resource that is not available indefinitely.
“The abolition of IPI opposition is not just a procedural change — it is a permanent closure of the lowest-cost validity challenge mechanism available against Swiss domestic patents. Companies that have identified challengeable blocking patents in their Swiss FTO analysis have until January 1, 2027 to use it. After that date, the same challenge requires Swiss Federal Patent Court nullity proceedings.”
Change Two: EPO-Comparable Scope — What It Means for FTO
How Swiss domestic patent scope changes: Current Swiss domestic patents are assessed under a scope standard that is similar to but not identical with the EPO approach. The difference is subtle in most technology areas but commercially material in sectors where claim scope boundaries determine infringement. The revised Act explicitly aligns Swiss domestic patent protection scope with EPO standards. From January 1, 2027, Swiss domestic patents offer protection comparable to European patents for the first time, removing the long-standing scope asymmetry between the two layers of the Swiss patent landscape.
Which technology areas are most affected: The scope alignment change matters most in technology sectors where claim scope is commercially decisive — precisely the sectors that dominate the Swiss domestic patent landscape. Pharmaceutical compound claims and formulation patents, where the boundary between infringing and non-infringing products can be narrow, are the category where EPO-comparable scope has the most significant practical effect. Medtech device claims covering component designs, manufacturing processes, and software-integrated systems are the second major category. Swiss precision technology patents covering manufacturing methods and materials are a third area where the scope alignment creates a material change in effective protection breadth.
FTO analyses done before January 2027 may underestimate scope: For companies with existing Swiss FTO analyses that assessed domestic Swiss patent risk under the pre-reform scope standard, the reform creates a specific reassessment requirement. A domestic Swiss patent that was assessed as narrow under the current standard may carry broader effective scope under the EPO-comparable post-reform standard. If that broader scope covers a product feature or claim element that the pre-reform assessment concluded was clear, the FTO conclusion needs updating.
The Pre-Reform Window: What to Do Before January 2027
The period before January 1, 2027 is a defined window with specific actions that will not be available after the reform takes effect. Managing this window well requires understanding both which actions are time-limited and which can be deferred. Our analysis of the 5 most common pitfalls in FTO analyses highlights that one of the most consistently missed FTO risks is the failure to account for upcoming legal framework changes that alter the scope or enforceability of blocking patents. The Swiss reform is exactly that kind of change — a defined date that creates a before-and-after FTO scope distinction.
- Identify blocking Swiss domestic patents currently within the IPI opposition window. Any Swiss domestic patent granted within the last 9 months that represents a genuine blocking risk for a planned Swiss product launch should be assessed for IPI opposition filing before the window closes permanently. This requires a targeted review of the IPI register for recently granted patents in your technology space, a validity pre-screen for each identified patent, and a decision on whether the validity risk justifies an opposition filing under the pre-reform procedure.
- Complete Swiss FTO analysis while the pre-reform scope standard still applies. For products launching in 2027 or later, completing a Swiss FTO under the pre-reform scope standard before January 1, 2027 gives a clean baseline. The analysis can then be updated for post-reform scope changes as a targeted scope extension rather than a full new FTO. This is a more efficient approach than commissioning a new full FTO after the reform takes effect, during the transition period when the post-reform scope standard is being applied for the first time.
- Assess SPC extensions under both pre- and post-reform scope standards. Swiss supplementary protection certificates for pharma and medtech products are not directly changed by the reform. But the underlying patent’s scope may change, which affects how SPC coverage should be assessed. For products where SPC-extended protection is part of the blocking patent picture, both the pre- and post-reform scope standards need to be applied to the underlying patent to give a complete picture of effective SPC coverage.
Post-Reform FTO: What a Complete Swiss Market Analysis Covers
A complete Swiss market FTO for a pharma or medtech product launching after January 2027 needs to cover five specific dimensions.
EPO-granted European patents validated in Switzerland: Assessed at their EPO scope under both pre- and post-reform standards — the reform does not directly change EPO patent scope, but the alignment of domestic Swiss scope with EPO standards affects how the two layers compare. SPC extensions assessed for both layers where applicable.
Swiss domestic IPI patents: Now assessed at EPO-comparable scope post-reform. Patents previously assessed under the narrower pre-reform standard need scope reassessment. The domestic layer is the one most directly changed by the reform and the layer most frequently underweighted in international FTO analyses.
Opt-out status and UPC long-arm reach: Switzerland is not a UPC participating state, so opt-out is not applicable to Swiss domestic patents. However, UPC long-arm jurisdiction confirmed in 2025 means UPC proceedings can reach Swiss products where defendants have connections to UPC participating states. The Swiss FTO needs to flag European patents in the relevant technology space that are not opted out of the UPC system.
IPI opposition status: Pre-reform: check opposition status and window for any recently granted domestic Swiss blocking patents. Post-reform: note that the absence of opposition on a post-reform patent carries no validity inference. FPC nullity pre-screening is the appropriate validity assessment for post-reform blocking patents.
FPC nullity viability for blocking candidates: For domestic Swiss patents that represent genuine blocking risks post-reform, a prior art pre-screen to assess whether FPC nullity proceedings would succeed is a core component of the FTO — replacing the IPI opposition assessment that served this purpose pre-reform.
How Our FTO Service Covers the Post-Reform Swiss Market
Our freedom to operate service covers both EPO-validated patents and domestic Swiss IPI patents under the post-2027 EPO-comparable scope standard, with SPC extension assessment for pharma and medtech products and UPC long-arm reach flagging for European patents not opted out of the UPC system. For companies with Swiss market entry planned around the January 2027 reform date, we structure FTO engagements to make use of the pre-reform IPI opposition window where relevant, complete scope assessment under the pre-reform standard to establish a baseline, and deliver a post-reform scope update identifying which conclusions change at the reform implementation date. For companies commissioning new Swiss FTO analyses after January 2027, we apply the EPO-comparable scope standard from the outset and include FPC nullity viability pre-screening for domestic Swiss patent blocking candidates.
Planning Swiss pharma or medtech market entry around the January 2027 Patent Act reform? Our FTO service covers the pre-reform IPI opposition window, the post-reform EPO-comparable scope standard, and the full domestic Swiss patent layer that most international analyses miss. → Contact Us
Conclusion: The Takeaway
Switzerland’s Patent Act reform is a defined, dated event with two specific FTO implications. The IPI opposition window closes permanently on January 1, 2027. The scope standard for domestic Swiss patents changes to EPO-comparable on the same date. Both changes affect the FTO picture for pharma and medtech companies planning Swiss market entry — one by closing a time-limited validity challenge opportunity, the other by broadening the effective scope of blocking patents that were previously assessed under a narrower standard.
The pre-reform window between now and January 1, 2027 is not a footnote. For companies with challengeable blocking Swiss domestic patents in their FTO, it is the last opportunity to use the lowest-cost validity challenge mechanism available against those patents. That opportunity closes on a known date. The FTO strategy that accounts for it is materially better positioned than the one that discovers it has passed.
